GA-ASI Achieves EMAR/FR 145 Maintenance Organization Approval for MQ-9A and MQ-9B Platforms
20.3.2025 13:00:00 CET | ACCESS Newswire | Press release
European Military Airworthiness Regulator Approves GA-ASI Application Approval Will Make Subsequent Certifications Easier
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 20, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI), a world leader in unmanned aircraft systems (UAS), has received the prestigious EMAR/FR 145 Maintenance Organization Approval for component maintenance from the French Military Continuing Airworthiness Authority, DSAE. This approval underscores GA-ASI's commitment to the highest standards of safety, compliance, and operational excellence in military aviation.
The EMAR framework is a set of regulations developed from commercial aerospace standards (FAA/EASA) that are designed to ensure airworthiness for European military aircraft. It establishes a common airworthiness framework recognized by military airworthiness authorities worldwide. EMAR/FR 145 certification authorizes maintenance organizations to perform critical maintenance tasks while ensuring strict adherence to safety, reliability, and documentation requirements.
GA-ASI's EMAR/FR 145 approval allows the company to issue EMAR Form 1s (Return to Service forms) for components serviced by the approved maintenance organization, confirming the safety and airworthiness of the equipment. This recognition applies to GA-ASI's maintenance activities at its Poway and Adelanto, California, facilities and covers CAT C (component maintenance) services.
"This approval is a significant achievement for GA-ASI, positioning the company to better serve international customers, especially military users of our MQ-9A and MQ-9B UAS platforms," said Sam Richardson, GA-ASI vice president of Sustainment. "The ability to leverage the EMAR/FR 145 certification streamlines the company's processes, reduces costs, and accelerates future airworthiness pursuits, as many future customers will recognize this certification rather than requiring a full, independent certification process."
By obtaining EMAR/FR 145 approval, GA-ASI further demonstrates its ability to meet the stringent demands of the global defense market. The framework's widespread recognition ensures that GA-ASI can expand operations and offer high-quality, compliant maintenance services to international customers, ultimately driving company growth in global markets.
This certification offers significant operational and financial benefits for both GA-ASI and its customers. For GA-ASI, the approval reduces future oversight costs by leveraging the DSAE Audit Team's oversight activities, ensuring a more efficient and cost-effective certification process for future non-French EMAR customers. For customers, the EMAR/FR 145 approval provides a framework recognized internationally, offering a streamlined maintenance certification process. The recognition agreements between EMAR and non-EMAR countries allow future customers to leverage GA-ASI's French approval, saving time and resources compared to a full certification effort.
About GA-ASI
General Atomics Aeronautical Systems, Inc. is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.
For more information, visit www.ga-asi.com.
Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.
# # #
Contact Information
GA-ASI Media Relations
asi-mediarelations@ga-asi.com
(858) 524-8101
SOURCE: General Atomics Aeronautical Systems, Inc.
View the original press release on ACCESS Newswire
General Atomics Aeronautical Systems, Inc.

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom